Cargando…
Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump
BACKGROUND AND AIM: The aim of this study is to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) using CyberKnife in the treatment of patients with recurrent pancreatic adenocarcinoma at the abdominal lymph node or stump after surgery. PATIENTS AND METHODS: Between Octo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935106/ https://www.ncbi.nlm.nih.gov/pubmed/27418841 http://dx.doi.org/10.2147/OTT.S102784 |
_version_ | 1782441416705703936 |
---|---|
author | Zeng, Xian-Liang Wang, Huan-Huan Meng, Mao-Bin Wu, Zhi-Qiang Song, Yong-Chun Zhuang, Hong-Qing Qian, Dong Li, Feng-Tong Zhao, Lu-Jun Yuan, Zhi-Yong Wang, Ping |
author_facet | Zeng, Xian-Liang Wang, Huan-Huan Meng, Mao-Bin Wu, Zhi-Qiang Song, Yong-Chun Zhuang, Hong-Qing Qian, Dong Li, Feng-Tong Zhao, Lu-Jun Yuan, Zhi-Yong Wang, Ping |
author_sort | Zeng, Xian-Liang |
collection | PubMed |
description | BACKGROUND AND AIM: The aim of this study is to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) using CyberKnife in the treatment of patients with recurrent pancreatic adenocarcinoma at the abdominal lymph node or stump after surgery. PATIENTS AND METHODS: Between October 1, 2006 and May 1, 2015, patients with recurrent pancreatic adenocarcinoma at the abdominal lymph node or stump after surgery were enrolled and treated with SBRT at our hospital. The primary end point was local control rate after SBRT. Secondary end points were overall survival, time to symptom alleviation, and toxicity, assessed using the Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Twenty-four patients with 24 lesions (17 abdominal lymph nodes and seven stumps) were treated with SBRT, of which five patients presented with abdominal lymph nodes and synchronous metastases in the liver and lung. The 6-, 12-, and 24-month actuarial local control rates were 95.2%, 83.8%, and 62.1%, respectively. For the entire cohort, the median overall survival from diagnosis and SBRT was 28.9 and 12.2 months, respectively. Symptom alleviation was observed in eleven of 14 patients (78.6%) within a median of 8 days (range, 1–14 days) after SBRT. Nine patients (37.5%) experienced Common Terminology Criteria for Adverse Events version 4.0 grade 1–2 acute toxicities; one patient experienced grade 3 acute toxicity due to thrombocytopenia. CONCLUSION: SBRT is a safe and effective treatment for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph node or stump after surgery. Further studies are needed before SBRT can be recommended routinely. |
format | Online Article Text |
id | pubmed-4935106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49351062016-07-14 Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump Zeng, Xian-Liang Wang, Huan-Huan Meng, Mao-Bin Wu, Zhi-Qiang Song, Yong-Chun Zhuang, Hong-Qing Qian, Dong Li, Feng-Tong Zhao, Lu-Jun Yuan, Zhi-Yong Wang, Ping Onco Targets Ther Original Research BACKGROUND AND AIM: The aim of this study is to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) using CyberKnife in the treatment of patients with recurrent pancreatic adenocarcinoma at the abdominal lymph node or stump after surgery. PATIENTS AND METHODS: Between October 1, 2006 and May 1, 2015, patients with recurrent pancreatic adenocarcinoma at the abdominal lymph node or stump after surgery were enrolled and treated with SBRT at our hospital. The primary end point was local control rate after SBRT. Secondary end points were overall survival, time to symptom alleviation, and toxicity, assessed using the Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Twenty-four patients with 24 lesions (17 abdominal lymph nodes and seven stumps) were treated with SBRT, of which five patients presented with abdominal lymph nodes and synchronous metastases in the liver and lung. The 6-, 12-, and 24-month actuarial local control rates were 95.2%, 83.8%, and 62.1%, respectively. For the entire cohort, the median overall survival from diagnosis and SBRT was 28.9 and 12.2 months, respectively. Symptom alleviation was observed in eleven of 14 patients (78.6%) within a median of 8 days (range, 1–14 days) after SBRT. Nine patients (37.5%) experienced Common Terminology Criteria for Adverse Events version 4.0 grade 1–2 acute toxicities; one patient experienced grade 3 acute toxicity due to thrombocytopenia. CONCLUSION: SBRT is a safe and effective treatment for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph node or stump after surgery. Further studies are needed before SBRT can be recommended routinely. Dove Medical Press 2016-06-30 /pmc/articles/PMC4935106/ /pubmed/27418841 http://dx.doi.org/10.2147/OTT.S102784 Text en © 2016 Zeng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zeng, Xian-Liang Wang, Huan-Huan Meng, Mao-Bin Wu, Zhi-Qiang Song, Yong-Chun Zhuang, Hong-Qing Qian, Dong Li, Feng-Tong Zhao, Lu-Jun Yuan, Zhi-Yong Wang, Ping Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump |
title | Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump |
title_full | Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump |
title_fullStr | Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump |
title_full_unstemmed | Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump |
title_short | Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump |
title_sort | stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935106/ https://www.ncbi.nlm.nih.gov/pubmed/27418841 http://dx.doi.org/10.2147/OTT.S102784 |
work_keys_str_mv | AT zengxianliang stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT wanghuanhuan stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT mengmaobin stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT wuzhiqiang stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT songyongchun stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT zhuanghongqing stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT qiandong stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT lifengtong stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT zhaolujun stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT yuanzhiyong stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump AT wangping stereotacticbodyradiationtherapyforpatientswithrecurrentpancreaticadenocarcinomaattheabdominallymphnodesorpostoperativestumpincludingpancreaticstumpandotherstump |